UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in NeoGenomics, Inc. (NASDAQ:NEO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 646,111 shares of the medical research company's stock after acquiring an additional 42,895 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.50% of NeoGenomics worth $10,648,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in NeoGenomics during the 4th quarter valued at $26,000. Sterling Capital Management LLC grew its position in NeoGenomics by 788.7% in the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after acquiring an additional 3,289 shares during the last quarter. Smartleaf Asset Management LLC grew its position in NeoGenomics by 203.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock valued at $70,000 after acquiring an additional 2,787 shares during the last quarter. Blue Trust Inc. grew its position in NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after acquiring an additional 1,103 shares during the last quarter. Finally, KBC Group NV grew its position in NeoGenomics by 44.7% in the 4th quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock valued at $108,000 after acquiring an additional 2,027 shares during the last quarter. Institutional investors own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

NEO has been the topic of several research analyst reports. Guggenheim initiated coverage on NeoGenomics in a research report on Thursday, May 15th. They issued a "neutral" rating on the stock. Leerink Partnrs downgraded NeoGenomics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Needham & Company LLC cut their price objective on NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Piper Sandler set a $12.00 price target on NeoGenomics and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $13.83.

Insider Buying and Selling at NeoGenomics

In other news, COO Warren Stone bought 5,700 shares of NeoGenomics stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $8.58 per share, with a total value of $48,906.00. Following the completion of the acquisition, the chief operating officer now directly owns 108,280 shares in the company, valued at $929,042.40. The trade was a 5.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Aaron Kelly purchased 5,000 shares of the stock in a transaction on Tuesday, May 27th. The shares were purchased at an average price of $7.60 per share, with a total value of $38,000.00. Following the acquisition, the director now directly owns 5,000 shares in the company, valued at $38,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 70,600 shares of company stock valued at $550,438 in the last quarter. Corporate insiders own 2.40% of the company's stock.

NeoGenomics Trading Down 0.4%

Shares of NASDAQ NEO traded down $0.03 during trading on Friday, reaching $7.34. The stock had a trading volume of 1,266,044 shares, compared to its average volume of 1,160,075. NeoGenomics, Inc. has a fifty-two week low of $6.08 and a fifty-two week high of $19.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The business's 50-day moving average price is $8.54 and its 200-day moving average price is $12.36. The company has a market cap of $944.62 million, a P/E ratio of -11.84 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $168.04 million during the quarter, compared to analysts' expectations of $171.38 million. During the same period in the prior year, the business earned ($0.02) EPS. The business's quarterly revenue was up 7.6% on a year-over-year basis. On average, equities research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.